VNRX shows severe liquidity deterioration with cash falling 66% to just $1.1M while current liabilities increased 57%, creating immediate funding pressure despite revenue growth and reduced R&D spending.
The company's cash position has collapsed to critically low levels of $1.1M while obligations have grown substantially, indicating potential near-term financing needs. Despite improving operational efficiency through R&D cost reductions and modest revenue growth, the balance sheet deterioration suggests management may need to secure additional funding or risk operational constraints.
VNRX demonstrated mixed operational progress with revenue growing 40% to $1.7M and R&D expenses declining 30% to $10.1M, contributing to improved operating cash flow performance. However, the balance sheet shows acute stress with cash reserves plummeting 66% to just $1.1M while current liabilities expanded 57% to $12.2M, and total debt increased 39% to $6.7M. The combination of minimal cash reserves against elevated obligations creates immediate liquidity concerns that overshadow the operational improvements.
Capex reduced 67.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Cash declined 65.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current liabilities surged 57% — significant near-term obligations; verify ability to meet short-term debt.
Current assets declined 49.2% — monitor working capital adequacy and short-term liquidity.
Strong top-line growth of 40% — accelerating demand or successful expansion into new markets.
Debt increased 39.4% — substantial leverage increase; assess whether deployed for growth or covering losses.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
R&D spending cut 30% — could signal cost discipline or concerning reduction in innovation investment.
Total assets contracted 26.6% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow grew 24% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →